



PTO/SB/08b (01-08)

Approved for use through 04/30/2008. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known

Application Number	10/788,606-Conf. #9642
Filing Date	February 27, 2004
First Named Inventor	Mary E. Brunkow
Art Unit	1646
Examiner Name	X. Xie
Attorney Docket Number	31173/40002

Sheet	1	of	8
-------	---	----	---

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	A1	US-2003/0165410-A1	09-04-2003	Taylor	
	A2	US-2003/0186915-A1	10-02-2003	Pan et al.	
	A3	US-2004/0009535-A1	01-15-2004	Brunkow et al.	
	A4	US-2004/0058321	03-25-2004	Brunkow et al.	
	A5	US-2004/0141875-A1	07-22-2004	Doshi	
	A6	US-2004/0146888-A1	07-29-2004	Paszty et al.	
	A7	US-2004/0158045	08-12-2004	Brunkow et al.	
	A8	US-2005/0106683-A1	05-19-2005	Winkler et al.	
	A9	US-2005/0238646-A1	10-27-2005	Ledbetter et al.	
	A10	US-2006/0233801	10-19-2006	Brunkow et al.	
	A11	US-2007/0110747	05-17-2007	Paszty et al.	
	A12	US-4,331,647	05-25-1982	Goldenberg	
	A13	US-4,411,993	10-25-1983	Gillis	
	A14	US-4,543,439	09-24-1985	Frackelton, Jr. et al.	
	A15	US-RE32,011	10-22-1985	Zimmerman et al.	
	A16	US-4,837,440	06-06-1989	Burtscher et al.	
	A17	US-4,902,614	02-20-1990	Wakabayashi et al.	
	A18	US-5,070,108	12-03-1991	Margolis	
	A19	US-5,145,684	09-08-1992	Liversidge et al.	
	A20	US-5,223,409	06-29-1993	Ladner et al.	
	A21	US-5,399,363	03-21-1995	Liversidge et al.	
	A22	US-5,466,468	11-14-1995	Schneider et al.	
	A23	US-5,543,158	08-06-1996	Gref et al.	
	A24	US-5,552,157	09-03-1996	Yagi et al.	
	A25	US-5,565,213	10-15-1996	Nakamori et al.	
	A26	US-5,567,434	10-22-1996	Szoka, Jr.	
	A27	US-5,627,052	05-06-1997	Schrader et al.	
	A28	US-5,641,515	06-24-1997	Ramtoola et al.	
	A29	US-5,698,426	12-16-1997	Huse	
	A30	US-5,738,868	04-14-1998	Shinkarenko et al.	
	A31	US-5,795,587	08-18-1998	Gao et al.	
	A32	US-5,877,397	03-02-1999	Lonberg et al.	
	A33	US-6,054,561	04-25-2000	Ring	
	A34	US-6,057,421	05-02-2000	Muller et al.	
	A35	US-6,117,911	09-12-2000	Grainger et al.	
	A36	US-6,133,426	10-17-2000	Gonzalez et al.	
	A37	US-6,207,153	03-27-2001	Dan et al.	
	A38	US-6,489,445	12-03-2002	Brunkow et al.	
	A39	US-6,495,736	12-17-2002	Brunkow et al.	
	A40	US-6,703,199	03-09-2004	Koide	
	A41	US-6,806,055-A1	10-19-2004	Berman et al.	
	A42	US-6,815,201-A1	11-09-2004	Pinter	
	A43	US-6,818,748-A1	11-16-2004	Fulton et al.	
	A44	US-7,192,583-A1	03-20-2007	Brunkow et al.	

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/788,606-Conf. #9642
				Filing Date	February 27, 2004
				First Named Inventor	Mary E. Brunkow
				Art Unit	1646
				Examiner Name	X. Xie
Sheet	2	of	8	Attorney Docket Number	31173/40002

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	B1	DE-102 55 152	06-03-2004	Lang Von Langen Ursula		
	B2	FR-2 838 379	10-17-2003	Valeo Climatisation		
	B3	JP-4-141095	05-14-1992	Chemo Sero Therapeut Res. Inst.		
	B4	WO-92/02551	02-20-1992	B R Centre Limited		
	B5	WO-95/30003	11-09-1995	Creative Biomolecules, Inc.		
	B6	WO-98/21335	05-22-1998	Genetics Institute, Inc.		
	B7	WO-99/06554	02-11-1999	Genset		
	B8	WO-99/03996	01-28-1999	Regeneron Pharmaceuticals, Inc.		
	B9	WO-99/15556	04-01-1999	Millennium Pharmaceuticals, Inc.		
	B10	WO-00/32773	06-08-2000	Darwin Discovery Ltd.		
	B11	WO-00/75317	12-14-2000	Genentech, Inc.		
	B12	WO-01/92308	12-06-2001	Amgen, Inc.		
	B13	WO-01/64885	09-07-2001	Amgen, Inc.		
	B14	WO-01/98491	12-27-2001	F. Hoffmann-La Roche AG		
	B15	WO-03/106657	12-24-2003	Stowers Institute for Medical Research		
	B16	WO-2005/003158	01-13-2005	Celltech R&D, Inc.		
	B17	WO-2005/014650	02-17-2005	Celltech R&D, Inc.		

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	C1	Altling-Mees et al., "Monoclonal Antibody Expression Libraries: A Rapid Alternative to Hybridomas," <i>Strategies in Molecular Biology</i> , 3:1-9 (1990).	
	C2	Alves et al., "Sclerosteosis: A Marker of Dutch Ancestry?" <i>Rev. Bras. Genet.</i> , 4:825-834 (1982).	
	C3	Angal et al., "A Single Amino Acid Substitution Abolishes the Heterogeneity of Chimeric	

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/788,606-Conf. #9642
				Filing Date	February 27, 2004
				First Named Inventor	Mary E. Brunkow
				Art Unit	1646
				Examiner Name	X. Xie
Sheet	3	of	8	Attorney Docket Number	31173/40002

		Mouse/Human (IgG4) Antibody," <i>Mol. Immunol.</i> , 30(1):105-108 (1993).	
	C4	Avsian-Kretcher et al., "Comparative Genomic Analysis of the Eight-Membered Ring Cystine Knot-Containing Bone Morphogenetic Protein Antagonists," <i>Mol. Endo.</i> , 18(10):1-12 (2004).	
	C5	Babcook et al., "A Novel Strategy for Generating Monoclonal Antibodies from Single, Isolated Lymphocytes Producing Antibodies of Defined Specificities," <i>Proc. Natl. Acad. Sci. (USA)</i> , 93:7843-7848 (1996).	
	C6	Baines et al., "Purification of Immunoglobulin G (IgG)," <i>Methods in Molecular Biology</i> , 10:79-104, The Humana Press, Inc. (1992).	
	C7	Balemans et al., "Extracellular Regulation of BMP Signaling in Vertebrates: A Cocktail of Modulators," <i>Dev. Biol.</i> , 250:231-250 (2002).	
	C8	Balemans et al., "Increased Bone Density in Sclerosteosis is due to the Deficiency of a Novel Secreted Protein (SOST)," <i>Hum. Mol. Genet.</i> , 10:537-543 (2001).	
	C9	Beighton et al., "The Clinical Features of Sclerosteosis," <i>Annals of Internal Medicine</i> , 84:393-397 (1976).	
	C10	Beighton et al., "The Syndromic Status of Sclerosteosis and van Buchem Disease," <i>Clinical Genetics</i> , 25:175-181 (1984).	
	C11	Berman et al., "The Protein Data Bank," <i>Acta. Cryst.</i> , 58(10):899-907 (2002).	
	C12	Bird et al., "Single-Chain Antigen-Binding Proteins," <i>Science</i> , 242:423-426 (1988).	
	C13	Birren et al., "Homo Sapiens chromosome 17, clone RP5-905N1," <i>EMBL Sequence Database</i> , AC003098.2 (2006).	
	C14	Black et al., "A Somatic Cell Hybrid Map of the Long Arm of Human Chromosome 17, Containing the Familial Breast Cancer Locus (BRCA1)," <i>Am. J. Hum. Genet.</i> , 52:702-710 (1993).	
	C15	Boden et al., "Glucocorticoid-Induced Differentiation of Fetal Rat Calvarial Osteoblasts is Mediated by Bone Morphogenetic Protein-6," <i>Endocrinology</i> , 138(7):2820-2828 (1997).	
	C16	Boerner et al., "Production of Antigen-Specific Human Monoclonal Antibodies from in Vitro-Primed Human Splenocytes," <i>J. Immunol.</i> , 147:86-95 (1991).	
	C17	Bondestam, "Ligands & Signaling Components of the Transforming Growth Factor," Helsinki University Biomedical Dissertations (2002).	
	C18	Bostrom et al., "Ligand & Signaling Components of the Transforming Growth Factor β Family," <i>J. Orth. Res.</i> , 13:357-367 (1995).	
	C19	Bowie et al., "A Method to Identify Protein Sequences that Fold into a Known Three-Dimensional Structure," <i>Science</i> , 253:164-170 (1991).	
	C20	Bradley et al., "Modifying the Mouse: Design and Desire," <i>Bio/Technology</i> , 10:534-539 (1992).	
	C21	Brenner et al., <i>Curr. Op. Struct. Biol.</i> , 7(3):369-376 (1997).	
	C22	Bruggemann et al., "Production of Human Antibody Repertoires in Transgenic Mice," <i>Curr. Opin. Biotechnol.</i> , 8:455-458 (1997).	
	C23	Burton et al., "Human Antibodies from Combinatorial Libraries," <i>Adv. Immunol.</i> , 57:191-280 (1994).	
	C24	Byrne et al., "CD4+CD45RB ^{hi} T Cell Transfer Induced Colitis in Mice is Accompanied by Osteopenia which is Treatable with Recombinant Human Osteoprotegerin," <i>Gut</i> , 54:78-86 (2005).	
	C25	Chandran et al., "Recent Trends in Drug Delivery Systems: Liposomal Drug Delivery System - Preparation and Characterisation," <i>Indian J. Exp. Biol.</i> , 35(8):801-809 (1997).	
	C26	Chou et al., "Empirical Predication of Protein Conformation," <i>Ann. Rev. Biochem.</i> , 47:251-276 (1979).	
	C27	Chou et al., Prediction of the Secondary Structure of Proteins from their Amino Acid Sequence," <i>Adv. Enzymol. Relat. Areas Mol. Biol.</i> , 47:45-148 (1978).	

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/788,606-Conf. #9642
				Filing Date	February 27, 2004
				First Named Inventor	Mary E. Brunkow
				Art Unit	1646
				Examiner Name	X. Xie
Sheet	4	of	8	Attorney Docket Number	31173/40002

C28	Clark, "Antibody Humanization: A Case of the 'Emperor's New Clothes'?", <i>Immunology Today</i> , 21(8):397-402 (2000).	
C29	Collins, "Identifying Human Disease Genes by Positional Cloning," <i>The Harvey Lectures</i> , Series 86:149-164 (1992).	
C30	Collins, "Positional Cloning Moves from Perditional to Traditional," <i>Nature Genetics</i> , 9:347-350 (1995).	
C31	Cochin, "Markers of Bone Metabolism," <i>Curr. Opin. in Rheu.</i> , 7:243 (1995).	
C32	Couvreux et al., "Polyalkylcyanoacrylates as Colloidal Drug Carriers," <i>Crit. Rev. Ther. Drug Carrier Syst.</i> , 5(1):1-20 (1988).	
C33	Crameri et al., "DNA Shuffling of a Family of Genes from Diverse Species Accelerates Directed Evolution," <i>Nature</i> , 391:288-291 (1998).	
C34	Dall'Acqua et al., "Antibody Humanization by Framework Shuffling," <i>Methods</i> , 36(1):43-60 (2005).	
C35	Ebara et al., "Mechanism for the Action of Bone Morphogenetic Proteins and Regulation of Their Activity," <i>Spine</i> , 27(165):S10-S15 (2002).	
C36	EMBL Accession No. AA393939	
C37	EMBL Accession No. AC003098	
C38	EMBL Accession No. AI113131	
C39	Epstein et al., "Endocrine Function in Sclerosteosis," <i>S. Afr. Med. J.</i> , 55:1105-1110 (1979).	
C40	Frost et al., "On the Rat Model of Human Osteopenias and Osteoporoses," <i>Bone and Mineral</i> , 18:227-236 (1992).	
C41	Gazzerro et al., "Bone Morphogenetic Proteins Induce the Expression of Noggin, Which Limits Their Activity in Cultured Rat Osteoblasts," <i>J. Clin. Invest.</i> , 102(12):2106-2114 (1998).	
C42	Genbank Accession No. AA393768	
C43	Genbank Accession No. BAA19765	
C44	Genbank Accession No. D38082	
C45	Genbank Accession No. D79813	
C46	Genbank Accession No. D89675	
C47	Genbank Accession No. NM 001203	
C48	Genbank Accession No. NM 001204	
C49	Genbank Accession No. NM 004329	
C50	Genbank Accession No. NM 030849	
C51	Genbank Accession No. NM 033346	
C52	Genbank Accession No. NP 001194	
C53	Genbank Accession No. S75359	
C54	Gitelman et al., "Vgr-1/BMP-6 Induces Osteoblastic Differentiation of Pluripotential Mesenchymal Cells," <i>Cell Growth & Differentiation</i> , 6:827-836 (1995).	
C55	Glasky et al., "Stability of Specific Immunoglobulin Secretion by EBV-Transformed Lymphoblastoid Cells and Human-Murine Heterohybridomas," <i>Hybridoma</i> , 8:377-389 (1989).	
C56	Green et al., "Antigen-Specific Human Monoclonal Antibodies from Mice Engineered with Human Ig Heavy and Light Chain YACs," <i>Nature Genet.</i> , 7:13 (1994).	
C57	Greene et al., "Screening Recombinant DNA Libraries," <i>Current Protocols in Molecular Biology</i> , Ch. 6(1) (1990).	
C58	Gribskov et al., "Profile Analysis," <i>Meth. Enzym.</i> , 183:146-159 (1990).	
C59	Gribskov et al., "Profile Analysis: Detection of Distantly Related Proteins," <i>Proc. Nat. Acad. Sci. (USA)</i> , 84(13):4355-4358 (1987).	
C60	Groeneveld et al., "Bone Morphogenetic Proteins in Human Bone Regeneration," <i>Eur. J.</i>	

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/788,606-Conf. #9642
				Filing Date	February 27, 2004
				First Named Inventor	Mary E. Brunkow
				Art Unit	1646
				Examiner Name	X. Xie
Sheet	5	of	8	Attorney Docket Number	31173/40002

		<i>Endocrinol.</i> , 142:9-21 (2000).	
	C61	Groppe et al., "Structural Basis of BMP Signaling Inhibition by the Cystine Knot Protein Noggin," <i>Nature</i> , 420:636-642 (2002).	
	C62	Guinness-Hey, "Increased Trabecular Bone Mass in Rats Treated with Human Synthetic Parathyroid Hormone," <i>Metab. Bone Dis. Relat. Res.</i> , 5:177-181 (1984).	
	C63	Harris, "Processing of C-Terminal Lysine and Arginine Residues of Proteins Isolated from Mammalian Cell Culture," <i>Journal of Chromatography</i> , 705:129-134 (1995).	
	C64	Hart et al., "Crystal Structure of the Human T β R2 Ectodomain-TGF- β 3 Complex," <i>Nat. Struc. Biol.</i> , 9(3):203-208 (2002).	
	C65	Heller et al., "Accession No. AA393768," <i>EMBL Sequence Database</i> , (1997).	
	C66	Hill et al., "Multiple Extracellular Signals Promote Osteoblast Survival and Apoptosis," <i>Endocrinology</i> , 138(9):3849-3858 (1997).	
	C67	Hock et al., "Perspective: Osteoblast Apoptosis and Bone Turnover," <i>J. Bone Miner. Res.</i> , 16(6):975-984 (2001).	
	C68	Hollinger et al., "Engineered Antibody Fragments and the Rise of Single Domains," <i>Nature Biotech.</i> , 23(9):1126-1136 (2005).	
	C69	Holm et al., "Protein Folds and Families: Sequence and Structure Alignments," <i>Nucl. Acid Res.</i> , 27(1):244-247 (1999).	
	C70	Hoogenboom et al., "By-Passing Immunisation: Human Antibodies from Synthetic Repertoires of Germline V μ Gene Segments Rearranged <i>in Vitro</i> ," <i>J. Molec. Biol.</i> , 227:381-388 (1992).	
	C71	Huse et al., "Generation of a Large Combinatorial Library of the Immunoglobulin Repertoire in Phage Lambda," <i>Science</i> , 246:1275-1281 (1989).	
	C72	Hwang et al., "Use of Human Germline Genes in a CDR Homology-Based Approach to Antibody Humanization," <i>Methods</i> , 36(1):35-42 (2005).	
	C73	Innis et al., "Evolutionary Trace Analysis of TGF- β and Related Growth Factors: Implications for Stie-Directed Mutagenesis," <i>Protein Engineering</i> , 13(12):839-847 (2000).	
	C74	Jakovovits et al., "Production of Antigen-Specific Human Antibodies from Mice Engineered with Human Heavy and Light Chain YACs," <i>Ann. N.Y. Acad. Sci.</i> , 764:525-535 (1995).	
	C75	Jee et al., "Overview: Animal Models of Osteopenia and Osteoporosis," <i>J. Musculoskel. Neuron. Interact.</i> , 1:193-207 (2001).	
	C76	Jilka et al., "Increased Bone Formation by Prevention of Osteoblast Apoptosis with Parathyroid Hormone," <i>J. Clin. Invest.</i> , 104:439-446 (1999).	
	C77	Jones, "Progress in Protein Structure Predication," <i>Curr. Opin. Struct. Biol.</i> , 7(3):377-387 (1997).	
	C78	Kabat et al., "Sequences of Proteins of Immunological Interest," U.S. Department of Health and Human Services, NIH, USA (1987) (Table of Contents).	
	C79	Kalu, The Ovariectomized Rat Model of Postmenopausal Bone Loss," <i>Bone and Mineral</i> , 15:175-192 (1991).	
	C80	Kang et al., "Linkage of Recognition and Replication Functions by Assembling Combinatorial Antibody Fab Libraries Along Phage Surfaces," <i>Proc. Natl. Acad. Sci. (USA)</i> , 88:4363-4366 (1991).	
	C81	Katagiri et al., "The Non-Osteogenic Mouse Pluripotent Cell Line, C3H10T1/2, is Induced to Differentiate into Osteoblastic Cells by Recombinant Human Bone Morphogenetic Protein-2," <i>Biochem. Biophys. Res. Comm.</i> , 172(1):295-299 (1990).	
	C82	Kawabata et al., "Signal Transduction by Bone Morphogenetic Proteins," <i>Cytokine and Growth Factor Reviews</i> , 9(1):49-61 (1998).	
	C83	Khalil, TGF- β : From Latent to Active," <i>Microbes and Infection</i> , 1(15):1255-1263 (1999).	
	C84	Kohler et al., "Continuous Cultures of Fused Cells Secreting Antibody of Predefined	

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/788,606-Conf. #9642
				Filing Date	February 27, 2004
				First Named Inventor	Mary E. Brunkow
				Art Unit	1646
				Examiner Name	X. Xie
Sheet	6	of	8	Attorney Docket Number	31173/40002

		Specificity," <i>Nature</i> , 256:495 (1975).	
	C85	Koli et al., "Latency, Activation, and Binding Proteins of TGF- β ," <i>Microscopy Res. Tech.</i> , 52:354-362 (2001).	
	C86	Koreth et al., "Microsatellites and PCR Genomic Analysis," <i>J. Pathology</i> , 178:239-248 (1996).	
	C87	Kramer et al., "The Gapped Duplex DNA Approach to Oligonucleotide-Directed Mutation Construction," <i>Nucleic Acids Res.</i> , 12:9441 (1984).	
	C88	Kunkel et al., "Rapid and Efficient Site-Specific Mutagenesis without Phenotypic Selection," <i>Methods in Enzymol.</i> , 154:367-382 (1987).	
	C89	Kunkel, "Rapid and Efficient Site-Specific Mutagenesis without Phenotypic Selection," <i>Proc. Natl. Acad. Sci. (USA)</i> , 82:488-492 (1985).	
	C90	Kusu et al., "Sclerostin is a Novel Secreted Osteoclast-Derived Bone Morphogenetic Protein Antagonist with Unique Ligand Specificity," <i>J. Biol. Chem.</i> , 278:24113-24117 (2003).	
	C91	Lasic, "Novel Applications of Liposomes," <i>Trends Biotechnol.</i> , 16(7):307-321 (1998).	
	C92	Latham, "The Biochemical and Cellular Characterization of Sclerostin, The Causative Gene for Sclerosteosis," <i>Calcified Tissue International</i> , 70(4):244 (2002).	
	C93	Liu et al., "Human Type II Receptor for Bone Morphogenetic Proteins (BMPs): Extension of the Two-Kinase Receptor Model to the BMPs," <i>Molecular and Cellular Biology</i> , 15(7):3479-3486 (1995).	
	C94	Lonberg et al., "Antigen-Specific Human Antibodies from Mice Comprising Four Distinct Genetic Modifications," <i>Nature</i> , 368:856 (1994).	
	C95	Low et al., "Mimicking Somatic Hypermutation: Affinity Maturation of Antibodies Displayed on Bacteriophage using a Bacterial Mutator Strain," <i>J. Mol. Biol.</i> , 250:350-368 (1996).	
	C96	Margalit, "Liposome-Mediated Drug Targeting in Topical and Regional Therapies," <i>Crit. Rev. Ther. Drug Carrier Syst.</i> , 12(2-3):233-261 (1995).	
	C97	Marks et al., "By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling," <i>Bio/Technology</i> , 10:779-783 (1992).	
	C98	Miyazono et al., "Divergence and Convergence of TGF- β /BMP Signaling," <i>J. Cell. Physiol.</i> , 187:265-276 (2001).	
	C99	Miyazono et al., "TGF- β Signaling by Smad Proteins," <i>Adv. Immunology</i> , 75:115-157 (2000).	
	C100	Moult, "The Current State of the Art in Protein Structure Prediction," <i>Curr. Opin. Biotech.</i> , 7(4):422-427 (1996).	
	C101	Nakase et al., "Transient and Localized Expression of Bone Morphogenetic Protein 4 Messenger RNA During Fracture Healing," <i>J. Bone Miner. Res.</i> , 9(5):651-659 (1994).	
	C102	Nelson, "Positional Cloning Reaches Maturity," <i>Current Opinion in Genetics and Development</i> , 5:298-303 (1995).	
	C103	Nickel et al., "The Crystal Structure of the BMP-2:BMPr-1A Complex and the Generation of BMP-2 Antagonists," <i>J. of Bone and Joint Surgery</i> , 83-A:S1-7 - S1-14 (2001).	
	C104	Nifuji et al., "Coordinated Expression of Noggin and Bone Morphogenetic Proteins (BMPs) During Early Skeletogenesis and Induction of Noggin Expression by BMP-7," <i>J. Bone Miner. Res.</i> , 14(12):2057-2066 (1999).	
	C105	Nisonoff et al., "Separation of Univalent Fragments from the Bivalent Rabbit Antibody Molecule by Reduction of Disulfide Bonds," <i>Arch. Biochem. Biophys.</i> , 89:230-244 (1960).	
	C106	Nygren et al., "Scaffolds for Engineering Novel Binding Sites in Proteins," <i>Curr. Opin. Struct. Biol.</i> , 7:463-469 (1997).	
	C107	Oelgeschlager et al., "The Evolutionarily Conserved BMP-Binding Protein Twisted Gastrulation Promotes BMP Signaling," <i>Nature</i> , 105:757-763 (2000).	
	C108	Oreffo et al., "Human Bone Marrow Osteoprogenitors Express Estrogen Receptor-Alpha and Bone Morphogenetic Proteins 2 and 4 mRNA During Osteoblastic Differentiation," <i>J. Cell.</i>	

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/788,606-Conf. #9642
				Filing Date	February 27, 2004
				First Named Inventor	Mary E. Brunkow
				Art Unit	1646
				Examiner Name	X. Xie
Sheet	7	of	8	Attorney Docket Number	31173/40002

		Biochem., 75:382-392 (1999).	
	C109	Patten et al., "Applications of DNA Shuffling to Pharmaceuticals and Vaccines," <i>Curr. Opin. Biotechnol.</i> , 8:724-733 (1997).	
	C110	Piek et al., "Specificity, Diversity, and Regulation of TGF- β Superfamily Signaling," <i>FASEB J.</i> , 13:2105-2124 (1999).	
	C111	Pietromonaco et al., "Protein Kinase C- α Phosphorylation of Moesin in the Actin-Binding Sequence," <i>J. Biol. Chem.</i> , 273:7594-7603 (1998).	
	C112	Pignatti et al., "Tracking Disease Genes by Reverse Genetics," <i>J. Psychiatr. Res.</i> , 26(4):287-298 (1992).	
	C113	Pluckthun et al., "Expression of Functional Antibody Fv and Fab Fragments in <i>Escherichia coli</i> ," <i>Methods Enzymol.</i> , 178:497-515 (1989).	
	C114	Porter, "The Hydrolysis of Rabbit γ -Globulin and Antibodies with Crystalline Papain," <i>Biochem. J.</i> , 73:119-126 (1959).	
	C115	Quintanar-Guerrero et al., "Preparation Techniques and Mechanisms of Formation of Biodegradable Nanoparticles from Preformed Polymers," <i>Drug Dev. Ind. Pharm.</i> , 24(12):1113-1128 (1998).	
	C116	Reddi, "Interplay Between Bone Morphogenetic Proteins and Cognate Binding Proteins in Bone and Cartilage Development: Noggin, Chordin and DAN," <i>Arthritis Res.</i> , 3(1):1-5 (2000).	
	C117	Sambrook et al., "Synthetic Oligonucleotide Probes," <i>Molecular Cloning - A Laboratory Manual</i> , Ch.11:11.1-11.19 and 11.58-11.61 (1989).	
	C118	Sanger et al., "DNA Sequencing with Chain-Terminating Inhibitors," <i>PNAS</i> , 74:5463-5467 (1977).	
	C119	Sastry et al., "Cloning of the Immunological Repertoire in <i>Escherichia coli</i> for Generation of Monoclonal Catalytic Antibodies: Construction of a Heavy Chain Variable Region-Specific cDNA Library," <i>Proc. Natl. Acad. Sci. (USA)</i> , 86:5728-5732 (1989).	
	C120	Scatchard et al., "The Attractions of Proteins for Small Molecules and Ions," <i>Ann. N.Y. Acad. Sci.</i> , 51:660-672 (1949).	
	C121	Scheufler et al., "Crystal Structure of Human Bone Morphogenetic Protein-2 at 2.7 Å Resolution," <i>J. Mol. Biol.</i> , 287(1):103-115 (1999).	
	C122	Schlebusch et al., "Production of a Single-Chain Fragment of the Murine Anti-Idiotypic Antibody ACA125 as Phage-Displayed and Soluble Antibody by Recombinant Phage Antibody Technique," <i>Hybridoma</i> , 16:47-52 (1997).	
	C123	Sigmund, "Viewpoint: Are Studies in Genetically Altered Mice Out of Control?" <i>Arterioscler. Thromb. Vasc. Biol.</i> , 20:1425-1429 (2000).	
	C124	Sippl et al., "Threading Thrills and Threats," <i>Structure</i> , 4(1):15-19 (1996).	
	C125	Sivakumar et al., "New Insights into Extracellular Matrix Assembly and Reorganization from Dynamic Imaging of Extracellular Matrix Proteins in Living Osteoblasts," <i>J. Cell. Sci.</i> , 119(7):1350-1360 (2006).	
	C126	Smith et al., "Glucocorticoids Inhibit Development Stage-Specific Osteoblast Cell Cycle," <i>J. Biol. Chem.</i> , 275:19992-20001 (2000).	
	C127	Sudo et al., "in Vitro Differentiation and Calcification in a New Clonal Osteogenic Cell Line Derived from Newborn Mouse Calvaria," <i>J. Cell Biol.</i> , 96:191-198 (1983).	
	C128	Sutherland et al., "Sclerostin Promotes the Apoptosis of Human Osteoblastic Cells: A Novel Regulation of Bone Formation," <i>Bone</i> , 35:828-835 (2004).	
	C129	Suzawa et al., "Extracellular Matrix-Associated Bone Morphogenetic Proteins are Essential for Differentiation of Murine Osteoblastic Cells in Vitro," <i>Endocrinology</i> , 140:2125-2133 (1999).	
	C130	Takakura, "Drug Delivery Systems in Gene Therapy," <i>Nippon Rinsho</i> , 56(3):691-695 (1998) (Abstract Only).	

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Complete if Known	
				Application Number	10/788,606-Conf. #9642
				Filing Date	February 27, 2004
				First Named Inventor	Mary E. Brunkow
				Art Unit	1646
				Examiner Name	X. Xie
Sheet	8	of	8	Attorney Docket Number	31173/40002

	C131	Tam et al., "TGF- β Receptor Expression on Human Keratinocytes: A 150 kDa GPI-Anchored TGF- β 1 Binding Protein Forms a Heteromeric Complex with Type I and Type II Receptors," <i>J. Cellular Biochem.</i> , 70:573-586 (1998).	
	C132	Taylor et al., "Human Immunoglobulin Transgenes Undergo Rearrangement, Somatic Mutation and Class Switching in Mice That Lack Endogenous IgM," <i>Int. Immun.</i> , 6:579 (1994).	
	C133	The Merck Manual-Second Home Edition, Ch. 61:1-3 (2005).	
	C134	Thompson et al., "Affinity Maturation of a High-Affinity Human Monoclonal Antibody Against the Third Hypervariable Loop of Human Immunodeficiency Virus: Use of Phage Display to Improve Affinity and Broaden Strain Reactivity," <i>J. Mol. Biol.</i> , 256:77-88 (1996).	
	C135	Thornton et al., "Prediction of Progress at Last," <i>Nature</i> , 354:105-106 (1991).	
	C136	Van Hul et al., "Van Buchem Disease (Hyperostosis Corticalis Generalisata) Maps to Chromosome 17q12-a21," <i>Am. J. Hum. Genet.</i> , 2:391-399 (1998).	
	C137	von Bubnoff et al., "Intracellular BMP Signaling Regulation in Vertebrates: Pathway or Network?" <i>Dev. Biol.</i> , 239:1-14 (2001).	
	C138	Wall, "Transgenic Livestock: Progress and Prospects for the Future," <i>Theriogenology</i> , 45:57-68 (1996).	
	C139	Wang, "Bone Morphogenetic Proteins (BMPs): Therapeutic Potential in Healing Bony Defects," <i>TIBTECH</i> , 11:379-383 (1993).	
	C140	Warmington et al., "Sclerostin Antagonism in Adult Rodents, via Monoclonal Antibody Mediated Blockade, Increases Bone Mineral Density and Implicates Sclerostin as a Key Regulator of Bone Mass During Adulthood," <i>J. Bone Min. Res.</i> , 19:S56-S57 (2004).	
	C141	Winter et al., "Making Antibodies by Phase Display Technology," <i>Annu. Rev. Immunol.</i> , 12:433-455 (1994).	
	C142	Wolff et al., "Monoclonal Antibody Homodimers: Enhanced Antitumor Activity in Nude Mice," <i>Cancer Res.</i> , 53:2560-2565 (1993).	
	C143	Yang et al., "CDR Walking Mutagenesis for the Affinity Maturation of a Potent Human Anti-HIV-1 Antibody into the Picomolar Range," <i>J. Mol. Biol.</i> , 254:392-403 (1995).	
	C144	Zambaux et al., "Influence of Experimental Parameters on the Characteristics of Poly(Lactic Acid) Nanoparticles Prepared by a Double Emulsion Method," <i>J. Controlled Release</i> , 50(1-3):31-40 (1998).	
	C145	Zhang et al., "Humanization of an Anti-Human TNF- α Antibody by Variable Region Resurfacing with the Aid of Molecular Modeling," <i>Molecular Immunology</i> , 42(12):1445-1451 (2005).	
	C146	zur Muhlen et al., "Solid Lipid Nanoparticles (SLN) for Controlled Drug Delivery - Drug Release and Release Mechanism," <i>Eur. J. Pharm. Biopharm.</i> , 45(2):149-155 (1998).	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.